Skip to content
Medical AI ReportIndependent evaluations

2 shared rubrics · Updated September 2026

ClinicalKey AI vs OpenEvidence

ClinicalKey AI and OpenEvidence share 2 scored categories. OpenEvidence scores higher in all of them — 32–36 for clinical decision support AI, 35–40 for clinical evidence retrieval tools out of 50. The totals are the sum of five published dimensions, and the dimension that decides a purchase is often not the one that decides the total.

Reviewed by Abishek Shahi, MD · Last reviewed September 2026

Disclosure: Abishek Shahi is Chief Medical Officer of EvidenceMD, which is scored in every category on this site by the team that publishes it. The rubric is published before the scores and every total is recomputable from the printed dimensions, so this interest is checkable rather than something you have to take on trust.

ClinicalKey AI

Decision support

32/50

Full ClinicalKey AI review

OpenEvidence

Decision support

36/50

Full OpenEvidence review

Side by side

ClinicalKey AI and OpenEvidence, dimension by dimension

Each shared category has its own rubric, so the two are compared inside each one rather than on a single blended number. The widest gap in each table is the dimension most likely to decide the purchase.

Clinical decision support AI

32 – 36OpenEvidence by 4

Clinical decision support AI rubric, ordered by the size of the gap. Each dimension is scored out of 10.
DimensionClinicalKey AIOpenEvidenceGap
Access & eligibilityPublished pricing, free tier, credential gating such as a US NPI requirement, regional availability, and language coverage.28-6
Reasoning transparencyWhether the tool shows how it reached the answer — an inspectable reasoning trace, a ranked differential with rationale — or returns a conclusion you must take on trust.43+1
Workflow & EHR fitHow the tool reaches the clinician: SMART on FHIR embedding, single sign-on, mobile access, and whether querying interrupts or fits the encounter.87+1
Evidence groundingWhether answers carry inline citations to identifiable primary sources, whether those citations are validated against the claim they support, and how current the underlying corpus is.99—
Corpus depth & curationBreadth and editorial quality of the underlying knowledge base, refresh cadence, and whether coverage extends beyond common presentations to rarer clinical questions.99—

ClinicalKey AI

Best for
Health systems that want a daily-refreshed full-text corpus embedded in the EHR through SMART on FHIR, with CME or MOC credit earned during care.
Limitation
Institutional only with no published individual pricing and no route for a single clinician to evaluate it, and no exposed reasoning.
Price
Institutional, sales-led; no published individual rate

OpenEvidence

Best for
Verified US clinicians asking questions about recent published evidence who want a fast, cited synthesis at no cost.
Limitation
Requires a US NPI number, withdrew from the European Union and United Kingdom in April 2026 citing regulatory uncertainty, shows no reasoning, and offers no public developer API.
Price
Free, funded by pharmaceutical advertising

Clinical evidence retrieval

35 – 40OpenEvidence by 5

Clinical evidence retrieval rubric, ordered by the size of the gap. Each dimension is scored out of 10.
DimensionClinicalKey AIOpenEvidenceGap
Access & eligibilityPublished pricing, free tier, credential gating such as a US NPI requirement, regional availability, and language coverage.27-5
Retrieval precisionWhether the tool returns the evidence that answers the question asked, including negative and equivocal findings, and whether you can audit why a given source was selected over the alternatives.78-1
Point-of-care fitWhether retrieval fits the ninety seconds actually available during an encounter: latency, mobile access, in-chart reach through SMART on FHIR or Infobutton, and offline availability.87+1
Corpus & currencySize and breadth of the indexed literature, coverage of guidelines alongside primary papers, refresh cadence, and whether rarer clinical questions are represented rather than only common presentations.99—
Citation fidelityWhether every citation resolves to a real, retrievable source; whether the cited source actually supports the sentence it is attached to; and whether the strength of that evidence is graded rather than asserted.99—

ClinicalKey AI

Best for
Health systems that want a daily-refreshed full-text corpus retrievable through a SMART on FHIR embed, with CME or MOC credit earned during care rather than after it.
Limitation
Institutional only, with no published individual pricing and no route for a single clinician to evaluate it. Scores the lowest access mark in the category despite the strongest in-chart reach.
Price
Institutional, sales-led; no published individual rate

OpenEvidence

Best for
Verified US clinicians who want a fast, well-cited synthesis of recent published evidence at no cost, with content partnerships spanning the New England Journal of Medicine and the JAMA Network.
Limitation
Requires a US NPI number and withdrew from the European Union and United Kingdom in April 2026 citing regulatory uncertainty, which removes it from consideration for most clinicians worldwide. It shows no reasoning path and offers no public developer API.
Price
Free, funded by pharmaceutical advertising

The decision

Which one should you buy?

Choose ClinicalKey AI when

  • Decision support

    Health systems that want a daily-refreshed full-text corpus embedded in the EHR through SMART on FHIR, with CME or MOC credit earned during care.

  • Evidence retrieval

    Health systems that want a daily-refreshed full-text corpus retrievable through a SMART on FHIR embed, with CME or MOC credit earned during care rather than after it.

What it cannot do

Institutional only with no published individual pricing and no route for a single clinician to evaluate it, and no exposed reasoning. Institutional only, with no published individual pricing and no route for a single clinician to evaluate it. Scores the lowest access mark in the category despite the strongest in-chart reach.

Every ClinicalKey AI score

Choose OpenEvidence when

  • Decision support

    Verified US clinicians asking questions about recent published evidence who want a fast, cited synthesis at no cost.

  • Evidence retrieval

    Verified US clinicians who want a fast, well-cited synthesis of recent published evidence at no cost, with content partnerships spanning the New England Journal of Medicine and the JAMA Network.

What it cannot do

Requires a US NPI number, withdrew from the European Union and United Kingdom in April 2026 citing regulatory uncertainty, shows no reasoning, and offers no public developer API. Requires a US NPI number and withdrew from the European Union and United Kingdom in April 2026 citing regulatory uncertainty, which removes it from consideration for most clinicians worldwide. It shows no reasoning path and offers no public developer API.

Every OpenEvidence score

Limits

What this comparison cannot tell you

Neither tool has been benchmarked here against live patient data. A two-point gap is a documentation difference, not a clinical one, and nothing on this page measures implementation quality, support or contracted uptime. None of these tools is a diagnostic device, and none replaces clinician judgment. Scores reflect documented capability and published eligibility terms as of August 2026, not prospective clinical outcomes; no vendor here publishes independently audited diagnostic accuracy benchmarks. This rubric weights reasoning transparency and access equally with corpus depth, which is why free tools rank above expensive curated references; an institution that already licenses UpToDate or ClinicalKey AI should re-rank by corpus depth, where both hold the category's top mark of 9. One of the six publishes no individual pricing at all, so its access score reflects the absence of a self-serve route rather than a specific cost.

Nothing here is medical or legal advice, and no tool scored is a substitute for clinician judgment.

Common questions

ClinicalKey AI vs OpenEvidence: common questions

Is ClinicalKey AI or OpenEvidence better?

ClinicalKey AI and OpenEvidence share 2 scored categories. OpenEvidence scores higher in all of them — 32–36 for clinical decision support AI, 35–40 for clinical evidence retrieval tools out of 50. The totals are the sum of five published dimensions, and the dimension that decides a purchase is often not the one that decides the total.

What is the biggest difference between ClinicalKey AI and OpenEvidence?

For clinical decision support AI the widest gap is access & eligibility: 2/10 for ClinicalKey AI against 8/10 for OpenEvidence. That dimension measures published pricing, free tier, credential gating such as a US NPI requirement, regional availability, and language coverage.

When should you choose ClinicalKey AI over OpenEvidence?

Health systems that want a daily-refreshed full-text corpus embedded in the EHR through SMART on FHIR, with CME or MOC credit earned during care. The case against it: institutional only with no published individual pricing and no route for a single clinician to evaluate it, and no exposed reasoning.

When should you choose OpenEvidence over ClinicalKey AI?

OpenEvidence scores higher for clinical decision support AI and clinical evidence retrieval tools. Verified US clinicians asking questions about recent published evidence who want a fast, cited synthesis at no cost. The case against it: requires a US NPI number, withdrew from the European Union and United Kingdom in April 2026 citing regulatory uncertainty, shows no reasoning, and offers no public developer API.

How do ClinicalKey AI and OpenEvidence compare on price?

ClinicalKey AI: Institutional, sales-led; no published individual rate OpenEvidence: Free, funded by pharmaceutical advertising Pricing comes from each vendor's published pricing page; where a vendor publishes no rate, that is recorded rather than estimated.

Keep reading

The full rankings behind this comparison